122 related articles for article (PubMed ID: 21500491)
21. Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practice.
Vallancien G; Emberton M; Alcaraz A; Matzkin H; van Moorselaar RJ; Hartung R; Harving N; Elhilali M;
BJU Int; 2008 Apr; 101(7):847-52. PubMed ID: 18321317
[TBL] [Abstract][Full Text] [Related]
22. Response to daily 10 mg alfuzosin predicts acute urinary retention and benign prostatic hyperplasia related surgery in men with lower urinary tract symptoms.
Emberton M; Lukacs B; Matzkin H; Alcaraz A; Elhilali M; Vallancien G
J Urol; 2006 Sep; 176(3):1051-6. PubMed ID: 16890690
[TBL] [Abstract][Full Text] [Related]
23. Alfuzosin 10 mg once daily improves sexual function in men with lower urinary tract symptoms and concomitant sexual dysfunction.
Seftel A
J Urol; 2005 Nov; 174(5):1940-1. PubMed ID: 16217354
[No Abstract] [Full Text] [Related]
24. Efficacy of alfuzosin and sildenafil combination in male patients with lower urinary tract symptoms.
Öztürk Mİ; Kalkan S; Koca O; Güneş M; Akyüz M; Karaman MI
Andrologia; 2012 May; 44 Suppl 1():791-5. PubMed ID: 22211956
[TBL] [Abstract][Full Text] [Related]
25. Benign prostatic hyperplasia (BPH) and prostatitis: prevalence of painful ejaculation in men with clinical BPH.
Nickel JC; Elhilali M; Vallancien G;
BJU Int; 2005 Mar; 95(4):571-4. PubMed ID: 15705082
[TBL] [Abstract][Full Text] [Related]
26. Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study.
Nishino Y; Masue T; Miwa K; Takahashi Y; Ishihara S; Deguchi T
BJU Int; 2006 Apr; 97(4):747-51, discussion 751. PubMed ID: 16536766
[TBL] [Abstract][Full Text] [Related]
27. Lower urinary tract symptoms (LUTS) and sexual dysfunction (SD): new targets for new combination therapies?
Sciarra A
Eur Urol; 2007 Jun; 51(6):1485-7. PubMed ID: 17275984
[No Abstract] [Full Text] [Related]
28. Symptom deterioration during treatment and history of AUR are the strongest predictors for AUR and BPH-related surgery in men with LUTS treated with alfuzosin 10 mg once daily.
Emberton M; Elhilali M; Matzkin H; Harving N; van Moorselaar J; Hartung R; Alcaraz A; Vallancien G;
Urology; 2005 Aug; 66(2):316-22. PubMed ID: 16098361
[TBL] [Abstract][Full Text] [Related]
29. Association between lower urinary tract symptoms and erectile dysfunction.
Aslan G; Cavus E; Karas H; Oner O; Duran F; Esen A
Arch Androl; 2006; 52(3):155-62. PubMed ID: 16574595
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of extended-release doxazosin and doxazosin standard in patients with concomitant benign prostatic hyperplasia and sexual dysfunction.
Kirby RS; O'Leary MP; Carson C
BJU Int; 2005 Jan; 95(1):103-9; discussion 109. PubMed ID: 15638905
[TBL] [Abstract][Full Text] [Related]
31. Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB.
Roehrborn CG; Kaplan SA; Kraus SR; Wang JT; Bavendam T; Guan Z
Urology; 2008 Nov; 72(5):1061-7; discussion 1067. PubMed ID: 18817961
[TBL] [Abstract][Full Text] [Related]
32. Long-term use of tamsulosin to treat lower urinary tract symptoms/benign prostatic hyperplasia.
Schulman CC; Lock TM; Buzelin JM; Boeminghaus F; Stephenson TP; Talja M;
J Urol; 2001 Oct; 166(4):1358-63. PubMed ID: 11547074
[TBL] [Abstract][Full Text] [Related]
33. [The positive effect of sildenafil on LUTS from BPH while treating ED].
Ying J; Yao D; Jiang Y; Ren X; Xu M
Zhonghua Nan Ke Xue; 2004 Sep; 10(9):681-3. PubMed ID: 15497711
[TBL] [Abstract][Full Text] [Related]
34. [A double-blind trial on the effect of alpha-adrenergic blocker (bunazosin hydrochloride) in the symptomatic treatment of prostatism].
Kumamoto Y; Yokoyama E; Tsukamoto T; Tsuchida S; Nishizawa O; Koshiba K; Ishibashi A; Ogawa A; Tomita Y; Aso Y
Hinyokika Kiyo; 1987 Oct; 33(10):1681-702. PubMed ID: 2451409
[TBL] [Abstract][Full Text] [Related]
35. Effectiveness of tamsulosin hydrochloride and its mechanism in improving nocturia associated with lower urinary tract symptoms/benign prostatic hyperplasia.
Yoshida M; Inadome A; Masunaga K; Nagata T; Yoshiyasu T
Neurourol Urodyn; 2010 Sep; 29(7):1276-81. PubMed ID: 20878997
[TBL] [Abstract][Full Text] [Related]
36. Phosphodiesterase-5 inhibitors for lower urinary tract symptoms in men.
Gales BJ; Gales MA
Ann Pharmacother; 2008 Jan; 42(1):111-5. PubMed ID: 18094344
[TBL] [Abstract][Full Text] [Related]
37. [Results of an epidemiologic surgery carried out with men 50-80 years of age to study urinary disorders, quality of life and sexual function].
Richard F; Lukacs B; Jardin A; Lanson Y; Chevret-Measson M; Grange JC; Navratil H
Prog Urol; 2001 Apr; 11(2):250-63. PubMed ID: 11400487
[TBL] [Abstract][Full Text] [Related]
38. [The questionnaire of integral assessment of male sexuality].
Kogan MI; Kireev AIu
Urologiia; 2009; (1):46-50. PubMed ID: 19432233
[TBL] [Abstract][Full Text] [Related]
39. Comparison of 25 and 75 mg/day naftopidil for lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective, randomized controlled study.
Yokoyama T; Kumon H; Nasu Y; Takamoto H; Watanabe T
Int J Urol; 2006 Jul; 13(7):932-8. PubMed ID: 16882058
[TBL] [Abstract][Full Text] [Related]
40. [Safety ov benign prostatic hyperplasia treatment with alpha-adrenoblocker dalphas].
Loran OB; Pushkar' DIu; Rasner PI
Urologiia; 2000; (2):3-5. PubMed ID: 11186726
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
